Cancerguard™ test | Exact Sciences
Exact Sciences logo
United States
Choose your country

Select to view the solutions available in your location.

Select
Cancel
Login
Patient login

Track orders, get results, manage personal information, and more.

Provider login

Order tests, track orders, get results, and more.

THE ERA OF MULTI-CANCER EARLY DETECTION IS JUST BEGINNING

Our goal is to fulfill its promise.

Cancerguard™ Logo.

At Exact Sciences, we’re pioneering a paradigm shift in cancer detection. The Cancerguard™ test in development is being designed to detect multiple cancers in their earliest stages from a single blood draw.1 So we can start to close the gaps that exist in today’s cancer screening.

Because if we can detect cancer early, we may be able to stay one step ahead of it.2,3

See our latest presented data on the evolution of a multi-biomarker class approach to multi-cancer early detection testing

VIEW POSTER

The upper hand against cancer

There is a moment when we all have the upper hand against cancer. It’s before the first signs and symptoms show up, when more options are on the table. But too often, early detection opportunities are unavailable or missed.1 Today, we only have routine screening tests for about one-third of diagnosed cancers.2* This means that many cancers go undetected until it’s too late.1

Our vision for the Cancerguard™ test aims to transform cancer screening.

*Calculated using estimated new diagnoses and deaths from cancers that have standard-of-care screening: breast, cervical, colorectal, and lung (high risk) against all sites.

For decades, Exact Sciences has been leading the way in cancer screening

Look through our work

We are developing the multi-cancer early detection (MCED) test of the future—the Cancerguard™ test

Follow our progress

We are growing thought leadership for the MCED field

Explore with us

The Cancerguard™ test is under development. The features above describe current development goals. It has not been cleared or approved by the US Food and Drug Administration or any other national regulatory authority.

References

  1. Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ Precis Oncol. 2018;2:23.
  2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024; doi:10.3322/caac.21820
  3. Douville C, Nobles C, Hwang HJ, et al. Multi-cancer early detection through evaluation of aneuploidy, methylation, and protein biomarkers in plasma. Poster presented at: ESMO Congress; September 9-13, 2022; Paris, France. Abstract 73P.